Related Experiment Video
Updated: Jan 12, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Comparative Effectiveness of Approved Biologics in Treating Moderate-To-Severe Allergic Asthma: A Systematic Review
Yuelu Li1,2, Huan Zong1,2, Mengying Fang1,2
1Department of Respiratory and Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Introduction:
The aim of this study was to conduct a network meta-analysis (NMA) of randomized controlled trials (RCTs) to compare the efficacy of various biologics for treating moderate-to-severe allergic asthma.
Methods:
This study conducted a comprehensive and systematic literature search in Cochrane Library, Embase, PubMed, and Web of Science databases from the inception to December 31, 2024. The data extracted from eligible literature were analyzed using the Cochrane Randomized Trials Risk of Bias 2 tool and Stata 18.0 program.
Results:
A total of 19 RCTs, involving 7,449 patients with moderate-to-severe allergic asthma, were included in this NMA. In terms of reducing exacerbations, benralizumab (mean difference (MD) = -0.47, 95% confidence interval (CI) [-0.82, -0.12]), dupilumab (MD = -0.47, 95% CI [-0.72, -0.21]), omalizumab (MD = -0.30, 95% CI [-0.42, -0.17]), and tezepelumab (MD = -0.81, 95% CI [-1.09, -0.54]) all demonstrated superior efficacy compared to placebo. Additionally, tezepelumab was markedly more advanced than omalizumab (MD = -0.52, 95% CI [-0.80, -0.23]). With regard to lung function improvement, dupilumab (MD = 0.16, 95% CI [0.07, 0.24]) and tezepelumab (MD = 0.08, 95% CI [0.03, 0.14]) both exceeded placebo. Regarding asthma control, dupilumab (MD = -0.40, 95% CI [-0.77, -0.04]) and omalizumab (MD = -0.49, 95% CI [-0.89, -0.08]) both effectively lowered scores on the asthma control questionnaire (ACQ) compared to placebo. For enhancing quality of life, omalizumab (MD = 0.62, 95% CI [0.21, 1.03]) significantly raised scores on the standardized asthma quality of life questionnaire (AQLQ [S]+12) relative to placebo.
Conclusion:
Considering its significant clinical advantages in reducing exacerbations and improving lung function, tezepelumab should be prioritized as a treatment option for moderate-to-severe allergic asthma.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: